#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

A Drosophila model of Pontocerebellar Hypoplasia reveals a critical role for the RNA exosome in neurons


Authors: Derrick J. Morton aff001;  Binta Jalloh aff002;  Lily Kim aff001;  Isaac Kremsky aff001;  Rishi J. Nair aff001;  Khuong B. Nguyen aff001;  J. Christopher Rounds aff002;  Maria C. Sterrett aff001;  Brianna Brown aff003;  Thalia Le aff001;  Maya C. Karkare aff001;  Kathryn D. McGaughey aff001;  Shaoyi Sheng aff001;  Sara W. Leung aff001;  Milo B. Fasken aff001;  Kenneth H. Moberg aff003;  Anita H. Corbett aff001
Authors place of work: Department of Biology, RRC 1021, Emory University, NE, Atlanta, Georgia, United States of America aff001;  Genetics and Molecular Biology Graduate Program, Emory University, NE, Atlanta, Georgia, United States of America aff002;  Department of Cell Biology, Emory University School of Medicine, Atlanta, Georgia, United States of America aff003;  Biochemistry, Cell and Developmental Biology Graduate Program, Emory University, NE, Atlanta, Georgia, United States of America aff004
Published in the journal: A Drosophila model of Pontocerebellar Hypoplasia reveals a critical role for the RNA exosome in neurons. PLoS Genet 16(7): e32767. doi:10.1371/journal.pgen.1008901
Category: Research Article
doi: https://doi.org/10.1371/journal.pgen.1008901

Summary

The RNA exosome is an evolutionarily-conserved ribonuclease complex critically important for precise processing and/or complete degradation of a variety of cellular RNAs. The recent discovery that mutations in genes encoding structural RNA exosome subunits cause tissue-specific diseases makes defining the role of this complex within specific tissues critically important. Mutations in the RNA exosome component 3 (EXOSC3) gene cause Pontocerebellar Hypoplasia Type 1b (PCH1b), an autosomal recessive neurologic disorder. The majority of disease-linked mutations are missense mutations that alter evolutionarily-conserved regions of EXOSC3. The tissue-specific defects caused by these amino acid changes in EXOSC3 are challenging to understand based on current models of RNA exosome function with only limited analysis of the complex in any multicellular model in vivo. The goal of this study is to provide insight into how mutations in EXOSC3 impact the function of the RNA exosome. To assess the tissue-specific roles and requirements for the Drosophila ortholog of EXOSC3 termed Rrp40, we utilized tissue-specific RNAi drivers. Depletion of Rrp40 in different tissues reveals a general requirement for Rrp40 in the development of many tissues including the brain, but also highlight an age-dependent requirement for Rrp40 in neurons. To assess the functional consequences of the specific amino acid substitutions in EXOSC3 that cause PCH1b, we used CRISPR/Cas9 gene editing technology to generate flies that model this RNA exosome-linked disease. These flies show reduced viability; however, the surviving animals exhibit a spectrum of behavioral and morphological phenotypes. RNA-seq analysis of these Drosophila Rrp40 mutants reveals increases in the steady-state levels of specific mRNAs and ncRNAs, some of which are central to neuronal function. In particular, Arc1 mRNA, which encodes a key regulator of synaptic plasticity, is increased in the Drosophila Rrp40 mutants. Taken together, this study defines a requirement for the RNA exosome in specific tissues/cell types and provides insight into how defects in RNA exosome function caused by specific amino acid substitutions that occur in PCH1b can contribute to neuronal dysfunction.

Keywords:

Drosophila melanogaster – Phenotypes – RNA interference – Neurons – RNA structure – Exosomes – Amino acid substitution – Small nucleolar RNA

Introduction

Precise production of both coding and non-coding RNAs requires regulation not only at the level of transcription but also at the post-transcriptional level to ensure precise processing and regulated turnover [13]. The significance of post-transcriptional control of gene expression is underscored by the number of diseases associated with defects in RNA processing, surveillance and/or decay machinery [4]. Specifically, mutations in genes encoding structural subunits of the ubiquitously expressed RNA exosome, a critical mediator of both RNA processing and decay, cause a variety of tissue-specific diseases [3, 5, 6].

The evolutionarily conserved RNA exosome complex, first identified in Saccharomyces cerevisiae [1, 2, 7], plays critical roles in RNA processing, decay and surveillance. The multi-subunit structure of the RNA exosome complex, which is conserved from archaea to humans, consists of ten subunits [1, 2, 8, 9]. In humans, the RNA exosome subunits are termed EXOSome Component (EXOSC) proteins. In S. cerevisiae and Drosophila, most RNA exosome subunits are termed Rrp proteins after the original yeast genetic screen for ribosomal RNA processing (rrp) mutants [7]. As illustrated in the Fig 1A, the complex is comprised of a catalytically inert core consisting of a hexameric ‘ring’ of catalytically inactive PH-like ribonuclease domain-containing core subunits ‘capped’ by a trimer of S1/KH putative RNA binding domain-containing cap subunits and a catalytically active 3’ to 5’ processive exo- and endoribonuclease, DIS3, which associates with the bottom of the ‘ring-like’ core. In S. cerevisiae, all core RNA exosome genes are essential [1, 2, 10]. Furthermore, in Drosophila all RNA exosome genes studied thus far (Dis3, Mtr3, Rrp6, Rrp41, Rrp42) are essential and required for normal fly development [1113]. Studies in mice have been limited to assessing the role of Exosc3 in B-cells ex vivo [14].

Fig. 1. The Rrp40 subunit of the RNA exosome is required for viability and proper mushroom body development in Drosophila.
The Rrp40 subunit of the RNA exosome is required for viability and proper mushroom body development in <i>Drosophila</i>.
(A) The RNA exosome is an evolutionarily conserved ribonuclease complex composed of nine structural subunits termed exosome components (EXOSC1-9)—three Cap subunits: EXOSC1; EXOSC2; EXOSC3, six Core Ring subunits: EXOSC4 (not visible); EXOSC5; EXOSC6; EXOSC7 (not visible); EXOSC8; EXOSC9, and a Catalytic Base subunit: Dis3. Mutations in the EXOSC3 gene encoding a cap subunit [light blue, labeled with 3 (termed Rrp40 in Drosophila)] cause PCH1b [6]. (B) Tissue-specific drivers as indicated were employed to knockdown Rrp40 in Drosophila. The percentage of flies eclosed (of expected) for the indicated genotypes is shown for a total of 300 flies for each genotype. (C) Diagram of the adult Drosophila mushroom body (MB) lobes depicting the vertical alpha (α) and alpha prime (α‘) neurons, the medially projecting (β) and beta-prime (β‘) neurons, and the γ neurons (green) as well as the ellipsoid body (EB) (gray ring). (D) Fasciclin II antibody (anti-FasII) was used to stain either control brains or brains with Rrp40 depleted from mushroom bodies (OK107>Gal4). Maximum intensity Z-stack projections of mushroom bodies are shown. β-lobes of control brains do not cross the mid-line and these brains have well-formed α-lobes. Rrp40-depleted mushroom bodies (OK107-Gal4>Rrp40IR) (n = 30) have β-lobes defects (white arrows) or have missing α- lobes.

Given that the RNA exosome is essential for viability in model organisms examined thus far, it was surprising when mutations in genes encoding RNA exosome subunits were identified as the cause of several tissue-specific genetic diseases [15]. Mutations in genes that encode structural subunits of the RNA exosome have now been linked to genetic diseases with distinct clinical presentations [reviewed in [16, 17]]. The first such example was the finding that recessive mutations in the EXOSC3 gene, encoding a structural RNA exosome cap subunit (Fig 1A), cause a neurologic disease termed Pontocerebellar Hypoplasia type 1b (PCH1b) [3, 18]. PCH1b is characterized by hypoplasia/atrophy of the cerebellum and pons that leads to severe motor and developmental delays with Purkinje cell abnormalities and degeneration of spinal motor neurons [1820]. Most individuals with PCH1b do not live beyond childhood. A number of missense mutations that cause single amino acid substitutions in conserved regions of EXOSC3 have been linked to PCH1b [6]. Of note, clinical reports indicate that the severity of PCH1b pathology is influenced by EXOSC3 allelic heterogeneity, suggesting a genotype-phenotype correlation [6, 2123]. These observations indicate that EXOSC3 plays a critical role in the brain and suggest specific functional consequences for amino acid changes linked to disease.

A previous study that modeled loss of EXOSC3 in zebrafish by knockdown with antisense morpholinos reported embryonic maldevelopment, resulting in small brain size and reduced motility [6]. While co-injection of wildtype zebrafish exosc3 mRNA could rescue these phenotypes, exosc3 containing mutations modeling PCH1b failed to rescue [6], suggesting that these mutations disrupt the normal function of EXOSC3. Other studies to assess the functional consequences of RNA exosome disease-linked amino acid changes in RNA exosome subunits have only been performed thus far in yeast [24, 25] providing little insight into how these specific changes could cause tissue-specific consequences. Thus, no studies have produced a genetic model to explore the functional consequences of amino acid changes that cause disease in a multi-cellular model in vivo.

In this study, we exploit Drosophila as a model to understand the tissue-specific roles and requirements for Rrp40, the Drosophila ortholog of EXOSC3. This system also provides an in vivo platform to test the functional consequences of amino acid substitutions linked to disease by employing CRISPR/Cas9 gene editing technology to create an allelic series of mutations to model the amino acid substitutions that occur in PCH1b. This work reveals a critical role for Rrp40 in neurons during development and demonstrates that mutations in Rrp40 in flies, which model genotypes in individuals with PCH1b, cause reduced viability, neuronal-specific behavioral phenotypes, and morphological defects in the brain. RNA-sequencing analysis reveals that Rrp40 mutants modeling different patient genotypes show differences in levels of mRNAs and ncRNAs that are specific to each mutant providing insight into the molecular basis for the phenotypes observed. For example, we identify the neuronal gene Arc1, a critical regulator of neuronal function as increased in the RNA-seq dataset for both Rrp40 mutants, underscoring the critical role the RNA exosome plays in regulating neuronal transcripts. Taken together, our results provide the first evidence for a critical function of the RNA exosome subunit Rrp40 in neurons. We show that the Drosophila model can be used to provide insight into tissue-specific function of the RNA exosome in vivo to explore the functional consequences of amino acid substitutions linked to distinct disease phenotypes.

Results

The RNA exosome subunit Rrp40 is essential for development

To examine in vivo requirements for Rrp40, we employed RNAi to deplete Rrp40 (TRiP HMJ23923) from specific tissues/cell types. Successful knockdown of Rrp40 using this RNAi was confirmed by immunoblotting (S1 Fig). This RNAi transgene targeting the Drosophila EXOSC3 homolog Rrp40 was used in combination with a small panel of four Gal4 lines with distinct expression patterns: Actin5c>Gal4 (global); elav>Gal4 (neurons); repo>Gal4 (glia); and Mhc>Gal4 (muscle) to define the requirement for EXOSC3. Expression of each Gal4 driver to deplete Rrp40 led to complete lethality, with no surviving adults (Fig 1B). This general developmental requirement for Rrp40 in multiple tissues is consistent with previous studies of other RNA exosome subunits in Drosophila [1113].

Rrp40 is required for proper development of the Drosophila mushroom body neurons

To explore the requirement for Rrp40 in brain development, we utilized one structure in the fly brain that is not essential for viability [26], the mushroom body (MB). As illustrated in Fig 1C, each MB contains α/α’ and β/β’ composed of bundled axons that project from a dorsally located group of ~2000 Kenyon cells [27, 28]. The β/β’ branches project medially toward the ellipsoid and fan-shaped bodies of the midbrain, while the α/α’ branches project dorsally [29, 30]. Ellipsoid body neurons normally project axons medially towards the midline and eventually form a closed ring structure [30]. The neuronal adhesion protein Fasciclin-II (FasII), which is enriched on α and β axon branches and regions of the Drosophila central complex [30], was used as a marker to assess the effect of loss of Rrp40 on MB structure. This analysis employed a Gal4 driver specific for MBs (OK107-Gal4) in combination with the RNAi transgene targeting Rrp40 (UAS-Rrp40RNAi; OK107-Gal4) to deplete Rrp40 specifically from MBs. Optical sectioning of FasII-stained fly brains reveals missing MB α- and β-lobes and outgrowth defects of β-lobes (arrows in 1D) in the flies with Rrp40 depleted from MBs. We also noted defects in the pattern of FasII staining of the ellipsoid body (EB) in Rrp40-depleted flies. Thus, Rrp40 loss in MBs affects the morphology of the MB α- and β-lobes as well as ellipsoid bodies.

Rrp40 is required for age-dependent function in neurons

To further investigate the requirement for Rrp40 in neurons, we employed an RNAi temperature shift strategy to bypass the embryonic requirement for Rrp40. As depicted in Fig 2A, a ubiquitously expressed, temperature-sensitive tubulin(tub)-Gal80ts transgene was used to deplete Rrp40 in combination with the panel of Gal4 drivers. RNAi was induced by a shift from the permissive to restrictive temperature (18°C to 29°C) 24 hours after egg laying. Global Rrp40 depletion (Actin5c>Gal4) using this temperature-shift still yielded no adults, indicating complete lethality; however, Rrp40 depletion at this time-point in neurons and glia produced some viable adults (Fig 2B). In contrast, depletion of Rrp40 from muscle caused only a mild survival defect. Intriguingly, adult survivors of neuronal Rrp40 depletion had severely reduced lifespans (~1–2 days) relative to both Gal4 driver alone and wildtype controls. By contrast, the lifespan of survivors of the glial or muscle depletion is indistinguishable from either control (Fig 2C).

Fig. 2. Rrp40 is required for age-dependent function in neurons.
Rrp40 is required for age-dependent function in neurons.
(A) A scheme to illustrate the approach to achieve temperature-sensitive knockdown of Rrp40 is shown: The Gal80ts allele shifts between 18°C (blue, RNAi off) and 29°C (red, RNAi on). E0 = 0hr embryo, L1/2/3 = 1st, 2nd or 3rd instar larvae; WPP = white prepupa. (B) The viability of flies in which temperature sensitive RNAi was employed to deplete Rrp40 24 hours post egg laying is shown. The viability of these post-embryonic RNAi survivors as percentage of flies eclosed (of expected) is shown for the indicated tissue-specific drivers. (C) Kaplan-Meier analysis of post-embryonic RNAi survivors for either control (Gal4 alone) or temperature sensitive knockdown (tub> Gal80ts) for the following tissue-specific drivers: Neuronal (elav>Gal4, n = 50); Muscle (Mhc>Gal4, n = 50); or Glial (repo>Gal4, n = 50). (D) Fasciclin II antibody (anti-FasII) staining of both wildtype control brain and three representative brains with temperature-sensitive neuronal depletion of Rrp40 (elav>Rrp40IR;tub>Gal80ts) are shown. Maximum intensity Z-stack projections of mushroom bodies are shown. β-lobes in control wildtype brains do not cross the mid-line and these brains have well-formed α and β-lobes (n = 30). Mushroom bodies from flies with Rrp40 depleted from neurons (elav>Rrp40IR;tub>Gal80ts) (n = 5) have thinned α-lobes (white arrows) and β-lobes that often project to the contralateral hemisphere and appear to fuse (black asterisks).

To assess the requirement for Rrp40 in neurodevelopment, we exploited this temperature shift strategy to knockdown Rrp40 expression in neurons in the developing brain (elav>Rrp40IR;tub>Gal80ts) and assess MB development by optical sectioning of FasII-stained brains. As shown in Fig 2D, pan-neuronal depletion of Rrp40 (elav>Rrp40IR;tub>Gal80ts) elicits MB defects, including thinned α-lobes and/or fused β-lobes (Fig 2D). In sum, these RNAi data argue for a strict requirement for Rrp40 and thus RNA exosome function in multiple tissues during embryonic development. Bypassing this embryonic requirement reveals an enhanced requirement for Rrp40 in neurons during later stages of development and adult homeostasis, including the branching and projection of axons into the α- and β-lobes.

PCH1b mutations engineered into the Rrp40 locus impair viability and shorten lifespan

A number of missense mutations encoding single amino acid substitutions in conserved regions of EXOSC3 have been linked to PCH1b [15]. As shown in Fig 3A, The EXOSC3/Rrp40 protein consists of three domains: an N-terminal domain, an S1 putative RNA binding domain, and a K-homology (KH) putative RNA binding domain. Human EXOSC3 Glycine 31 [G31] and the analogous Drosophila G11 residue are located in a conserved region within the N-terminal domain, while EXOSC3 Aspartate 132 [D132] and the analogous Drosophila D87 residue are located in a conserved region within the S1 domain (Fig 3A).

Fig. 3. Generation of Drosophila models of PCH1b amino acid substitutions.
Generation of <i>Drosophila</i> models of PCH1b amino acid substitutions.
(A) The EXOSC3/Rrp40 protein consists of three domains: an N-terminal domain (N), a central S1 putative RNA binding domain, and a C-terminal putative RNA binding KH (K homology) domain. The disease-causing amino acid substitutions (G31A and D132A) modeled in Drosophila in this study are indicated in red above the domain structure. The position and flanking sequence of the amino acid substitutions in PCH1b-associated human EXOSC3 (shown in red) and the corresponding amino acids in Mus musculus (Mm), Drosophila melanogaster (Dm), and Saccharomyces cerevisiae (Sc) are shown. The percent identity/similarity between the human and Drosophila domains is indicated. (B) The amino acid substitutions that occur in EXOSC3 in patients that are modeled in Drosophila Rrp40, are indicated with Patient Genotype (Homozygous/Heterozygous) as modeled in Drosophila (Drosophila Genotype) shown. For each Drosophila model, the viability of that genotype engineered in flies by CRISPR/Cas9 gene editing is shown as % eclosed (of expected). Rrp40 mutants show decreased viability, indicated by skewed Mendelian ratios. n = the number of individual flies analyzed. The G11A over null genotype has not been reported in patients-indicated as not detected (ND) under patient genotype. (C) A Kaplan-Meier analysis shows that Rrp40 mutant flies with the indicated genotypes to model patient genotypes exhibit early adult lethality compared to wildtype Control flies (w1118) or Rrp40-WT (Rrp40wt) flies that have undergone CRISPR/Cas9 gene editing to produce a control wildtype Rrp40 allele (see Materials and methods).

We utilized CRISPR/Cas9-mediated genome editing technology to create alleles of Rrp40 corresponding to amino acid substitutions in EXOSC3 that cause PCH1b disease (Fig 3B). As illustrated in Fig 3B, Drosophila allows for true modeling of both homozygous and heterozygous alleles that cause disease. In parallel, a control Rrp40 chromosome was also created using a wildtype Homology Directed Repair (HDR) donor template to create flies we refer to as Rrp40wt that had undergone the same editing process as flies with engineered base substitutions. As described in Materials and methods and illustrated in S2 Fig, all three Rrp40 alleles (Rrp40wt, Rrp40G11A, and Rrp40D87A) contain the 3xP3-DsRed cassette inserted in the intergenic region downstream of the Rrp40 3’UTR, which allows for visual sorting by red fluorescence in eye tissue. The HDR donor templates containing 3xP3-DsRed were injected into nos-Cas9 embryos. To confirm targeting events in DsRed-positive flies, genomic DNA was amplified and sequenced in the Rrp40 wildtype (Rrp40wt) control flies and in flies containing missense mutations (independent flies, n = 5) (Rrp40G11A and Rrp40D87A) (S3 Fig).

Initial analysis of these missense Rrp40 alleles revealed reduced homozygote viability to adulthood within intercrosses of heterozygous parents (Rrp40G11A: 14% of expected, n = 126, and Rrp40D87A: 38% of expected, n = 182) (Fig 3B). In contrast, Rrp40wt control flies eclose at a rate comparable to wildtype. The numbers of surviving adults were further reduced by placing Rrp40G11A or Rrp40D87A over a genomic deletion ((2L) Exel600) that removes the Rrp40 locus, suggesting that both of these missense alleles are hypomorphs, rather than amorphs or hypermorphs (Fig 3B). The lower viability of the Rrp40G11A allele, either in trans to itself or to (Df(2L) Exel6005), indicates that this is a stronger loss-of-function allele than Rrp40D87A.

Significantly, flies with the engineered Rrp40wt allele have a similar lifespan to control wildtype (w1118) flies within the tested 30-day testing period, showing that the 3xP3-DsRed cassette inserted into the intergenic region downstream of Rrp40 does not appreciably impair survival (Fig 3C). Thus, Rrp40wt was included as a control for subsequent studies. In contrast to Rrp40wt, Kaplan-Meier plots of Rrp40G11A homozygotes and Rrp40D87A homozygotes reveal significantly impaired survival, with all Rrp40G11A animals dead by day 14 and all Rrp40D87A homozygotes dead by day 25 (Fig 3C). We are also able to assess the lifespan of flies with the Rrp40D87A allele in trans to a deficiency (Df(2L) Exel6005), which mimics a reported patient genotype (Fig 3C) [6]. These flies have the shortest lifespan of all genotypes analyzed. As no flies with Rrp40G11A in trans to a deficiency (Df(2L) Exel6005) were produced, we could not assess lifespan. Indeed, no patient with EXOSC3 Glycine 31 [G31] over a deletion has been reported (Not detected, ND in Fig 3B).

Rrp40 mutant flies exhibit age-dependent morphological and behavioral defects

Rrp40G11A and Rrp40D87A adult survivors exhibit wing posture and behavioral defects that are consistent with neurological deficits [31]. Rrp40G11A and Rrp40D87A adults position their wings in an abnormal “held-up and held-out” posture rather than folding them together over the dorsal surface of the thorax and abdomen (Fig 4A) and this phenotype worsens with age (Fig 4B). Rrp40G11A and Rrp40D87A mutant animals also show reduced locomotor activity in a negative geotaxis assay that becomes more severe with age (Fig 4C). Both genotypes also display bouts of spasm interposed with periods of paralysis (S1, S2 and S3 Videos) relative to age-matched control Rrp40wt flies. The severity of the wing posture and locomotor defects among Rrp40 alleles follow a similar pattern: Rrp40G11A causes a more severe phenotype than Rrp40D87A, which is in turn is enhanced by (Df(2L) Exel6005). Notably, this pattern of phenotypes mimics the pattern of disease severity observed among individuals with PCH1b [15].

Fig. 4. Flies that model PCH1b amino acid substitutions in Drosophila show a range of morphological and behavioral phenotypes.
Flies that model PCH1b amino acid substitutions in <i>Drosophila</i> show a range of morphological and behavioral phenotypes.
(A) Rrp40 mutant flies show a progressive wing position phenotype in adults. Abnormal wing posture phenotypes (wings held-up or -out) are shown for Rrp40 mutant flies compared to Rrp40-WT flies with Days post-eclosion indicated for each representative image. (B) Quantitative analysis of the abnormal wing position phenotype of Rrp40 mutants raised at 25°C. The percentages of adults with abnormal wing position over time (Days post-eclosion) were calculated based on 60 flies per genotype. Neither w1118 nor Control Rrp40-WT flies showed any abnormal wing position (0% abnormal wing posture, n>100) over the time course analyzed. (C) Locomotor activity was assessed using a negative geotaxis assay as described in Materials and methods. Data are presented as the average percentage of flies of the indicated genotypes that reach the top of a cylinder after 60 seconds across all trials. Groups of 10 age-matched flies [Day (1) and Day (6)] were tested for at least three independent trials per genotype. Values represent the mean ± SEM for n = 3 independent experiments. Asterisks (*) indicate results that are statistically significance at *p-value < 0.05; **p<0.01. Results that show no statistical significance when compared are indicated by NS.

Rrp40G11A mutant flies have a mushroom body β-lobe midline-crossing defect

We analyzed MB structure in wildtype and Rrp40 mutants by immunostaining for FasII in whole adult brains. Confocal microscopy of Rrp40wt flies (n = 18), reveals no apparent MB defects in bifurcation or projection of α- and β-lobes neurons (Rrp40wt, Fig 5A). In contrast, brains of Rrp40G11A mutants show β-lobe fibers encroaching toward the midline, 56% (n = 23) (Fig 5A), sometimes sufficient to cause apparent fusion of the left and right β-lobes (Fig 5A). In contrast, Rrp40D87A mutant flies (n = 18) show no detectable defects in α- or β-lobes (Rrp40D87A, Fig 5).

Fig. 5. Rrp40G11A mutant flies show defects in mushroom body morphology.
<i>Rrp40</i><sup><i>G11A</i></sup> mutant flies show defects in mushroom body morphology.
Three representative images of merged projections of FasII-stained mushroom bodies from Rrp40-WT control flies (n = 18) (top row), Rrp40G11A (G11A/G11A) mutant flies (n = 23) (middle row), and Rrp40D87A (D87A/D87A) mutant flies (n = 18) (bottom row) are shown. In control flies, β-lobes do not cross the mid-line and well-formed α and β-lobes are readily apparent. In Rrp40G11A mutant flies, 13/23 (57%) brains examined showed defects in β-lobe structure or β-lobe fusion (white arrows). Neither β-lobe defect was detected in the Rrp40D87A mutant flies.

Pan-neuronal expression of human EXOSC3 is sufficient to rescue behavioral phenotypes in Rrp40 mutant flies

To both ensure that phenotypes observed are due to the engineered Rrp40 mutations and explore functional conservation between Rrp40 and human EXOSC3, we created transgenic flies that express human EXOSC3-myc from a UAS inducible promoter. The UAS-EXOSC3-myc transgene was expressed in the neurons (elav>Gal4) or muscle (Mhc>Gal4) of Rrp40 mutant animals (Fig 6A). Notably, UAS-EXOSC3-myc produced a mild but consistent rescue of Rrp40 mutant locomotor defects in the absence of the Gal4 driver (rescue control, Fig 6B), suggesting leaky expression from the transgene. Addition of the elav>Gal4 (neuronal) driver led to a robust rescue of climbing behavior: Rrp40 mutant animals with neuronal expression of EXOSC3 (elav>EXOSC3) perform normally in locomotor assays (Fig 6B); however, Rrp40 mutant animals with expression of EXOSC3 in muscle (Mhc>EXOSC3) did not show any statistically significant rescue (Fig 6B). Thus, human EXOSC3 can restore functions that are lacking in adult Rrp40 mutant neurons. This phenotypic rescue also confirms that the locomotor phenotype observed is due to the introduced CRISPR/Cas9 mutations.

Fig. 6. Locomotor defects in Rrp40 mutant flies are rescued by neuronal expression of human EXOSC3.
Locomotor defects in <i>Rrp40</i> mutant flies are rescued by neuronal expression of human <i>EXOSC3</i>.
(A) Transgenic flies that express myc-tagged human EXOSC3 under a UAS were generated as described in Materials and methods. The percentages of flies eclosed (of expected) for the indicated genotypes which include flies with transgenic EXOSC3, but no driver (rescue control), flies with the UAS and a pan-neuronal driver (elav) (pan-neuronal rescue), or the UAS and a muscle driver (Mhc) are shown for each Rrp40 mutant. (B) Locomotor assays were employed to assess whether expression of human EXOSC3 rescues behavioral phenotypes in Rrp40 mutant flies (G11A/G11A or D87A/D87A) in either neurons (elav) or muscle (Mhc). Data are presented as the average percentage of flies that reach the top of a cylinder after 60 seconds across all trials. Groups of 10 age-matched flies (Day 6) were tested for at least three independent trials per genotype. Results are shown for control Rrp40-WT flies as compared to either Rrp40G11A (G11A/G11A, top) or Rrp40D87A (D87A/D87A, bottom) homozygous flies that either do not express human EXOSC3 (-) or do express human EXOSC3 (+Gal4) in either neurons (elav) (Neuronal, left) or muscle (Mhc) (Muscle, right). Values represent the mean ± SEM for n = 3 independent experiments. Asterisks (*) indicate results that show statistical significance at *p-value < 0.05; **p<0.01. Results that show no statistical significance when compared are indicated by NS.

Steady-state levels of RNA exosome subunit levels are affected in Rrp40 mutant flies

Amino acid substitutions in Rrp40 could alter protein steady-state levels or impact the levels of other RNA exosome complex components. To test this possibility in vivo, we compared wildtype and Rrp40 variant levels in fly heads. As shown in Fig 7A, we performed immunoblotting of RNA exosome cap subunits (Rrp4 and Rrp40) and a core ring subunit (Mtr3) (see Fig 1A). We quantitated the results for Rrp40 and Rrp4, which reveals that levels of these cap subunits are modestly reduced in Rrp40 mutant fly heads (Fig 7B) compared to control. However, the decrease in levels of Rrp40 and Rrp4 is not statistically significantly different between the two mutants, suggesting these decreases are not sufficient to explain the phenotypic differences detected.

Fig. 7. Amino acid substitutions that model PCH1b in Rrp40 alter levels of RNA exosome subunits.
Amino acid substitutions that model PCH1b in Rrp40 alter levels of RNA exosome subunits.
(A) Lysates prepared from heads of control Rrp40wt or Rrp40 mutant flies were resolved by SDS-PAGE and analyzed by immunoblotting with antibodies to detect RNA exosome Cap Subunits, Rrp40/EXOSC3 and Rrp4/EXOSC2, and Core Subunit Mtr3/EXOSC6. Both LaminD and Stain Free, as a measure of total protein, serve as loading controls. (B) Results from (A) were quantitated for RNA exosome cap subunits levels (Rrp40 and Rrp4- bands for Mtr3 had too much background to yield reproducible results) and are presented as Relative Protein Levels with the value from the control Rrp40-WT flies set to 1.0. Asterisks (*) indicate results that show statistical significance at *p-value< 0.05. Results that show no statistical significance when compared are indicated by NS.

RNA-sequencing analysis of Rrp40 alleles reveals distinct gene expression profiles

To identify relevant RNA targets of the RNA exosome, we performed RNA-Seq analysis on three biological replicates of adult heads for each of the following genotypes (Rrp40wt, Rrp40G11A and Rrp40D87A) from newly eclosed (Day 0) flies. Unbiased principal component analysis (PCA) of the resulting RNA expression data produced three distinct clusters (Fig 8A), indicating that each PCH1b-linked Rrp40 allele alters the steady-state transcriptome relative to control Rrp40wt. The transcriptomes of the two missense Rrp40 mutants also differ from one another but not to same degree that either mutant differs from wildtype.

Fig. 8. RNA-seq analysis of Rrp40 mutant flies identifies key neuronal targets that are altered.
RNA-seq analysis of <i>Rrp40</i> mutant flies identifies key neuronal targets that are altered.
(A) Principal component analysis (PCA) analysis of RNA-seq data from adult Drosophila heads from Rrp40-WT and Rrp40 mutant flies (Rrp40G11A and Rrp40D87A) shows that results from the three independent experiments cluster based on the genotype and that mutants are more distinct from control flies than from one another. (B,C) Volcano plots show transcripts differentially expressed in each Rrp40 mutant [(B) G11A/G11A (2,351) and (C) D87A/D87A (3,502)] compared to Rrp40-WT (q<0.05, DEseq). The number of transcripts that show ≥ 5-fold change in steady-state levels (Down or Up) are indicated to the side in each plot. Representative regulators of neuronal function in flies (Arc1 and Or82a) are highlighted. (D) A correlation curve comparing the changes in gene expression relative to wildtype for each Rrp40 allele (G11A/G11A and D87A/D87A) was produced by plotting on a logarithmic scale. This analysis shows that the changes in transcript levels are highly correlated (R = 0.85) with respect to both magnitude and direction. (E) A pie chart illustrates the class of RNAs affected in each Rrp40 mutant by showing total RNAs increased at least 5-fold in each Rrp40 mutant corresponding to coding (mRNA) and non-coding RNA (ncRNA). (F) A pie chart illustrates the classes of ncRNAs increased at least 5-fold in each Rrp40 mutant (lncRNAs, long noncoding RNAs; asRNAs, Antisense RNAs; tRNAs, transfer RNAs; snoRNAs, small nucleolar RNAs; sisRNAs, stable intronic sequence RNAs; scaRNAs, small Cajal body RNAs). (G) The enriched pathways from FlyEnrichr database for Human Disease from Flybase are shown for transcripts that are increased at least 1.2-fold in each Rrp40 mutant (left, G11A/G11A; right, D87A/D87A) as compared to Rrp40-WT. The bars shown in green correspond to significant enrichment (Adj. p-val<0.05).

The high degree of reproducibility amongst the RNA-Seq replicates allowed us to identify transcripts that show statistically significant changes in each of the Rrp40 mutant backgrounds relative to wildtype controls (Fig 8B and 8C and S2 and S3 Tables). Consistent with the primary role of the RNA exosome in RNA decay [32], the majority of gene expression changes detected for Rrp40G11A (Fig 8B) or Rrp40D87A (Fig 8C) compared to Rrp40wt are increases in steady-state RNA transcript levels. To illustrate this point, of the 385 transcripts that change 5-fold or more in the Rrp40G11A mutant sample, 337 (88%) are increased (q<0.05), while of the 435 (84%) transcripts that change 5-fold or more in the Rrp40D87A mutant sample, 366 (84%) (q<0.05) are increased. The total transcriptomic changes in the mutant Rrp40 alleles show high correlation (R = 0.85) to one another based on comparing each Rrp40 mutant to wildtype (Fig 8D). This analysis suggests a correlation in both the direction and magnitude of transcriptomic changes.

To provide some insight into the transcripts that are likely to be direct targets of the RNA exosome in this first analysis in neuronal tissues, we analyzed transcripts that show a 5-fold or more increase in steady-state levels. Of the total number of altered transcripts that change 5-fold or more, a majority are mRNAs (61% in Rrp40G11A and 66% in Rrp40D87A) and the remainder include several classes of ncRNAs (Fig 8E). The different classes of effected ncRNAs include lncRNA, snoRNA, asRNA, tRNA, scaRNA and sisRNA (Fig 8F). We assessed whether the Rrp40G11A and Rrp40D87A alleles show an increase in overlapping or distinct sets of RNAs (q<0.05, >5-fold change). Consistent with the correlation coefficient comparing overall expression changes (Fig 8D), we found many coordinately increased coding and non-coding transcripts between the two groups, but also some RNAs that were only increased >5-fold in one of the mutants (S4 Fig).

FlyEnrichr analysis (FlyEnrichr; amp.pharm.mssm.edu/FlyEnrichr/) of coding transcripts significantly increased (q<0.05, >1.2-fold change) in Rrp40G11A and Rrp40D87A heads identified enriched pathways linked to human disease, including frontotemporal dementia, amyotrophic lateral sclerosis, and neurodegenerative disease (Fig 8G).

RNA-sequencing analysis reveals increased steady-state levels of key neuronal genes in Rrp40 mutant flies

RNA-sequencing analysis revealed increased steady-state levels of multiple functionally important neuronal genes including Arc1 [Rrp40G11A (30-fold increase); Rrp40D87A (16-fold increase)], Or82a [Rrp40G11A (35-fold increase); Rrp40D87A (2-fold increase)], PNUTS [Rrp40G11A (3-fold increase); Rrp40D87A (3-fold increase)], WFS1 [Rrp40G11A (7-fold increase); Rrp40D87A (6-fold increase)], and knon [Rrp40G11A (24-fold increase); Rrp40D87A (17-fold increase)] in Rrp40 mutants (Fig 9). We show Integrated Viewer (IGV) tracks generated from the RNA-seq dataset for Arc1 (Fig 9A) as well as Or82a, PNUTS, WFS1 and knon (CG7813) (S5A–S5D Fig). To validate altered gene expression from RNA-seq analysis, qRT-PCR was performed. This analysis confirmed that steady-state levels of Arc1 mRNA in Rrp40 mutants (Rrp40G11A and Rrp40D87A) id significantly increased as compared to control (Rrp40wt) (Fig 9B). As an additional measure of validation by RT-qPCR, we analyzed CG8617 (Fig 9B), a neighboring gene of Arc1 that showed no change in RNA-seq reads (Fig 9A). To extend the validation, we analyzed target transcripts increased in both Rrp40 mutants compared to Rrp40wt, including Or82a, PNUTS, WFS1 and knon (Fig 9C). These results validate our RNA-seq analysis as well as highlight transcripts that may be potential regulators of neuronal function, providing candidates to help define the molecular mechanism for the phenotypes observed in both Rrp40 mutants. Next, we tested whether expression of wildtype human EXOSC3 (UAS-EXOSC3-myc) only in neurons could rescue increased steady-state levels of validated transcripts, Arc1 and WFS1. RT-qPCR confirmed that steady-state levels of these transcripts are significantly decreased compared to control UAS alone (-), when EXOSC3 is expressed in neurons using a Gal4 driver (+Gal4) (Fig 9D), providing evidence for molecular rescue by human EXOSC3 to complement rescue of behavioral phenotypes (Fig 6B).

Fig. 9. Key neuronal transcripts show an increase in steady-state levels in Rrp40 mutant flies.
Key neuronal transcripts show an increase in steady-state levels in <i>Rrp40</i> mutant flies.
(A) An Integrative Genomic View (IGV) screenshot (http://software.broadinstitute.org/software/igv/) of Arc1 track peaks across the Drosophila genome (dm6 assembly) in Rrp40 mutants [Rrp40 D87A/D87A (Upper) and Rrp40 G11A/G11A (Middle)] as well as Rrp40-WT (WT, Lower). Chromosome number and location (red rectangle; top) are displayed at the top. (B,C) Changes in the level of representative transcripts were validated using RT-qPCR in Rrp40-WT and Rrp40 mutant flies. Data are presented as the Fold Change Normalized to Act5c transcript (which was unchanged in the RNA-Seq datasets) where the value for the Rrp40-WT sample is set to 1.0. Results are presented as mean ± standard error of the mean (*p<0.05;**p<0.01;***p<0.001;****p<0.0001 vs. the WT group in a two-tailed t-test). (D) Expression of human EXOSC3 (UAS-EXOSC3-myc) in neurons rescues the increased steady-state levels of the Arc1 (left) and WFS1 (right) transcripts in both Rrp40 mutants (G11A/G11A or D87A/D87A). The steady-state levels of the Arc1 and WFS1 transcripts were analyzed using RT-qPCR in control Rrp40-WT flies (set to 1.0) and mutant flies expressing human EXOSC3 (+Gal4) or not (-). Data are presented as the means ± standard error of the mean (*p<0.05;**p<0.01 vs. the WT group in a two-tailed t-test).

Discussion

In this study, we generated a Drosophila model to explore the requirement for RNA exosome function in specific tissues/cell types and define the functional consequences of amino acid substitutions in structural subunits of this complex that are linked to human disease. We provide evidence that the Drosophila Rrp40 subunit is essential for a critical step in early development. We also define an age-dependent requirement for Rrp40 in neurons critical for later stages of development and adult homeostasis. We extended this analysis to model genotypes that occur in PCH1b. These Rrp40 missense mutations cause reduced viability and produce neuronal-specific behavioral phenotypes that align with PCH1b severity, revealing a genotype-phenotype correlation. The Rrp40G11A mutant flies show defects in mushroom body morphology, highlighting the neurodevelopmental requirement for Rrp40. RNA-sequencing of the brain-enriched transcriptome of Rrp40 mutant flies identifies specific changes in both coding RNAs, including the synaptic regulator Arc1, and non-coding RNAs. Consistent with impaired RNA exosome activity the majority of transcripts that change show an increase in steady-state levels. These data establish a critical role for the RNA exosome in neurons and provide an initial characterization of the functional consequences of amino acid changes that underlie PCH1b in vivo using a multicellular organism.

Previous studies of the RNA exosome have provided evidence that individual subunits of this complex are essential in the organisms analyzed [1, 2, 1012, 14]. Thus, identification of mutations in genes encoding structural subunits of the RNA exosome that cause tissue-specific pathology was unexpected. In fact, only a few studies have explored the requirement for the RNA exosome in any specific tissues or cell types [12, 13, 3335]. Prior work using methods to deplete individual subunits of the complex in Drosophila revealed that these subunits are essential [12, 36]. More recent work examining the role of the EXOSC3 subunit in human embryonic stem cells built on studies that have implicated the RNA exosome in restraining differentiation [3335]. If there are specific requirements for the RNA exosome that are most critical for the development and/or homeostasis of certain cells or tissues, this could explain why mutations that impair the function of this complex preferentially affect certain tissues. Indeed, our studies exploiting Drosophila uncover an age-dependent requirement for Rrp40 in neurons. However, mutations in multiple genes that encode structural subunits of the RNA exosome termed exosomopathies, including two cap subunit genes, EXOSC3 [6, 21, 3739] and EXOSC2 [5], and two core subunit genes, EXOSC8 [3] and EXOSC9 [40, 41], have now been linked to genetic diseases with a variety of clinical presentations reported. The finding that multiple mutations that likely impair the function of the RNA exosome cause different clinical consequences is not consistent with a simple model where a defined tissue or cell type is highly dependent on the function of this complex. Rather the missense mutations that have been identified in multiple RNA exosome subunit genes likely impair tissue-specific functions of this complex. Indeed, although the number of patients for any given exosomopathy is small, there are now multiple missense mutations that have been identified [15], raising the questions of whether different amino acid changes that occur within the same RNA exosome gene impair the function of the complex in the same manner or to the same extent. A combination of approaches can be employed to understand how the amino acid changes that occur in patients affect the function of the RNA exosome.

This study uncovered at least two requirements for Rrp40. As with other RNA exosome subunits [6, 12, 13], depletion of Rrp40 globally or in multiple tissues causes complete lethality. This reveals an essential role for the RNA exosome in early development. When we bypass this early requirement, depletion of Rrp40 in neurons causes a decreased lifespan, which is not observed for other cell types. Modeling PCH1b mutations in Rrp40 allowed us to assess age-dependent functional consequences of these amino acid changes. These PCH1b model flies show a number of behavioral and morphological changes linked to altered neuronal function [31, 42]. Consistent with predicted neuronal dysfunction, depletion or mutation of Rrp40 is sufficient to cause morphological defects in MBs including the loss of α-lobes and defective β-lobe axon extension. These defects argue that Rrp40 function is required for proper axon guidance and neurite extension within the brain.

We employed the Gal4-UAS system to demonstrate that neuronal expression of human EXOSC3 is sufficient to rescue climbing deficits and molecular phenotypes in Rrp40 mutants. In contrast to expression in neurons, expression of EXOSC3 in muscle does not rescue climbing defects (Fig 6B). Neuronal expression of EXOSC3 could also restore multiple transcripts that increase in Rrp40 mutant flies to normal levels. Interestingly, while locomotor function is rescued in Rrp40 mutants by neuronal-specific expression of EXOSC3, viability is not. These findings suggest that there is an early developmental requirement for Rrp40 that EXOSC3 cannot replace; however, EXOSC3 is sufficient to replace Rrp40 in adult homeostasis.

There are multiple mechanisms by which a single amino acid substitution could impair RNA exosome function (Fig 10). Ultimately, any of these mechanistic consequences would alter RNA exosome activity toward target RNAs. Changes in all or a subset of these RNAs could cause pathology.

Fig. 10. Mechanistic model for how amino acid substitutions could alter RNA exosome function.
Mechanistic model for how amino acid substitutions could alter RNA exosome function.
(A) The Wildtype RNA exosome (top) associates with a variety of cofactors (purple) that can aid in target RNA recognition (middle) and decay/processing (bottom). (B) Amino acid substitutions that occur in the EXOSC3/Rrp40 cap subunit (shown in blue) could impact the function of the complex through multiple mechanisms, including: (a) decrease the steady-state level of the specific subunit or alter interaction of the subunit with the complex, leading to a decrease in overall Levels or altered Complex Integrity; (b) affect Cofactor Interactions, which could impact interactions with target RNAs; and/or (c) could directly alter interactions with target RNAs (red RNA indicates impaired interaction). Ultimately, any of these changes could Alter Activity Toward Specific Target RNAs. Changes in the steady state level or processing of RNAs could then cause downstream Disease Pathology.

The wildtype RNA exosome associates with cofactors to facilitate both decay and processing of target RNAs (Fig 10A) [32]. In the mutant case, levels of the individual subunit or the overall assembled complex could decrease (a). In fact, a previous study using patient fibroblast and myoblasts to examine variants of EXOSC8, an RNase (PH)-like domain-containing core ‘ring’ subunit linked to another form of PCH [40, 41], not only showed reduced levels of the EXOSC8 variants, but also EXOSC3, indicating that defects in core ‘ring’ subunits of the RNA exosome can lead to a reduction in other subunits [3]. This finding is rather surprising given that the patients analyzed did not exhibit pathology related to the cell types analyzed. While our data show a modest decrease in levels of Rrp40 and an associated cap subunit Rrp4 (Fig 7), two lines of evidence suggest this decrease is not sufficient to explain the phenotypes reported in this study. First, both Rrp40 alleles examined show a similar decrease in levels of Rrp40 as well as Rrp4, but Rrp40G11A mutant flies consistently show more severe phenotypes than Rrp40D87A flies (Figs 3B, 3C, 4 and 5). Furthermore, analysis of flies with a deficiency that removes the Rrp40 gene, creating flies with a single copy of Rrp40, do not display any of the phenotypes detected in the engineered Rrp40 mutant flies. These deficiency flies should have a 50% decrease in levels of Rrp40, which is a larger decrease than we detected in either Rrp40 mutant fly (Fig 7B).

In addition to overall loss of the complex, amino acid changes in the RNA exosome could alter interactions with cofactors (b). Indeed, structural studies of the budding yeast RNA exosome show that the nuclear RNA exosome cofactor Mpp6 interacts with the Rrp40 cap subunit [43, 44], and that an amino acid change in Rrp40 that models a change found in PCH1b decreases the interaction of Mpp6 with the RNA exosome [44]. The idea that interactions with specific cofactors could be perturbed by the amino acid changes that occur in disease is attractive because altered interactions with cofactors in different tissues or cell types could explain the phenotypic variation observed for mutations within the same EXOSC gene or the different EXOSC subunit genes that are linked to distinct diseases. RNA exosome cofactors have not been studied in Drosophila. The Rrp40 mutant flies described here could be a valuable tool for future genetic studies to define such cofactors.

Given that EXOSC3/Rrp40 is a cap subunit, amino acid substitutions could also directly impair interactions with target RNAs (c). In budding yeast, the three cap subunits of the RNA exosome make direct contact with target RNAs [9, 43], making this mechanistic consequence a formal possibility, Future studies will be required to understand how the different amino acid changes that occur in PCH1b impair the function of the RNA exosome.

As a first approach to consider how amino acid substitutions in EXOSC3 could impact the overall RNA exosome complex, we can take advantage of the availability of structures of this large macromolecular complex [8, 9, 43, 45, 46]. While there is no structure available of the Drosophila RNA exosome, the considerable evolutionary conservation illustrated in Fig 3B provides some context to consider how distinct amino acid changes in EXOSC3/Rrp40 could impair RNA exosome function. As shown in Fig 3A, the amino acid changes modeled in this study lie within the N-terminal (G31A) and S1 (D132A) domains of EXOSC3/Rrp40. The G31 residue in EXOSC3 packs against the surface of EXOSC5 and, therefore, the EXOSC3-G31A substitution could impair the interaction of EXOSC3 with EXOSC5 [8]. The D132 residue in EXOSC3 is located in a loop between strands in the S1 domain and the D132A substitution could thus impair the folding of the loop and, subsequently, disturb interactions between EXOSC5 and EXOSC9 [8]. These observations suggest that PCH1b amino acid changes in EXOSC3 could impair interactions with other RNA exosome subunits, leading to compromised RNA exosome complex integrity; however, wholesale loss of the RNA exosome seems unlikely to explain the phenotypic variability reported in PCH1b [47].

Here, we focused on defining the spectrum of RNA targets that are affected when Rrp40 function is impaired. To address this aspect of the mechanistic model (Fig 10B), we performed RNA-Seq analysis, providing the first dataset of candidate RNA exosome targets in brain tissue. Our brain-enriched RNA-sequencing data on Rrp40 mutant flies shows a global increase in transcripts and specific differences in both coding and non-coding transcripts in each Rrp40 mutant compared to control (Fig 8B and 8C). The finding that more RNAs show an increase in steady-state levels as compared to a decrease is consistent with impairing the function of a complex required for RNA turnover. Our results show significant correlation between the transcriptomic changes in Rrp40G11A flies and Rrp40D87A flies (Fig 8D), but also some clear differences both in the identity of the transcripts effected (S4 Fig) and the magnitude of the effects (Fig 9). The specific transcripts altered, the magnitude of the changes in the same transcripts or sets of transcripts, or a combination of these effects could underlie the phenotypic differences in the Rrp40 mutant flies analyzed. Future studies, including additional models, will be required to define how changes in the transcriptome contribute to these phenotypic differences.

Levels of a critical synaptic regulator, Arc1, are markedly increased in both Rrp40 mutants, suggesting that the RNA exosome regulates key neuronal transcripts. Notably, Arc1 levels increase more in the Rrp40G11A flies compared to Rrp40D87A, consistent with a model where the magnitude of changes in key regulators could contribute to phenotypic variation. Critically, these data provide insight into how amino acid changes in Rrp40 could disrupt processing and/or decay of transcripts required for proper development/maintenance of the nervous system.

In this study, we modeled three patient genotypes associated with PCH1b (Fig 3B). The analysis reveals a range of phenotypes, suggesting a genotype-phenotype correlation. Furthermore, the spectrum of phenotypes observed in flies modeling alleles of PCH1b aligns with some aspects of genotype-phenotype correlations reported for individuals with PCH1b, albeit the clinical phenotype are highly variable [39, 47], suggesting that these amino acid changes differentially impact RNA exosome activity. For example, homozygous PCH1b EXOSC3 p.Gly31Ala mutations [6, 20, 39], modeled as Drosophila Rrp40G11A, cause severe phenotypes (Fig 4). In contrast, homozygous PCH1b EXOSC3 p.Asp132Ala mutations, modeled as Drosophila Rrp40D87A, cause more moderate phenotypes as compared to the Rrp40G11A mutant flies. Moreover, PCH1b EXOSC3 p.Asp132Ala in trans to a presumptive EXOSC3 null mutation, modeled as Drosophila Rrp40D87A/Df(2L) causes the most severe patient phenotypes [6], arguing that D132A is likely hypomorphic. Interestingly, EXOSC3 p.Gly31Ala in trans to a presumptive EXOSC3 null has not been reported, and the lethality of the corresponding genotype Rrp40G11A/Df(2L) in flies (Fig 3B) suggests that human G31A and Drosophila G11A are strong loss of function alleles. While the fly models can provide insight into genotype-phenotype correlation, it is important to note that pathology and/or disease severity could arise from a combination of effects, and these combined effects could be specific to the genetic background of the patients. Critically, the number of reported individuals with EXOSC3-related PCH1b is small [6, 20, 3739, 48], thus limiting the ability to make genotype-phenotype correlations in patients and highlighting the value of the fly model.

In summary, this study identifies an essential role for Rrp40 in early development in Drosophila together with an age-dependent requirement for Rrp40 in neurons. Using CRISPR/Cas9 gene editing technology and Drosophila genetic approaches, we modeled PCH1b-linked EXOSC3 amino acid changes in Rrp40, which reveals neuronal-specific phenotypes and defines RNA targets critical for neuronal function. Strikingly, both behavioral phenotypes of Rrp40 mutant flies and levels of RNA targets are rescued by pan-neuronal transgenic expression of human EXOSC3. Taken together, these results demonstrate that this model can be utilized to explore the broader consequences of amino acid changes in the RNA exosome.

Materials and methods

Drosophila stocks

Crosses were maintained in standard conditions at 25°C unless otherwise noted. Stocks used in this study: w1118, UAS-Rrp40RNAi (TRiP HMJ23923, BDSC #63834), Df(2L)Exel6005 (BDSC #7492), Tub>Gal80ts (BDSC #7017), and the following Gal4 stocks: Actin5c>Gal4 (BDSC#25374), elav>Gal4 (BDSC#458), repo>Gal4 (BDSC#7415) and Mhc>Gal4 (BDSC#55133) were obtained from the Bloomington Drosophila Stock Center. Rrp40G11A and Rrp40D87A were generated by CRISPR/Cas9 editing (detail below) at Bestgene, Inc. (CA).

Brain dissections and immunohistochemistry

Brain dissections and staining were performed as described previously [49]. Briefly, brains of anesthetized animals were dissected in PTN buffer (0.1M NaPO4, 0.1% Triton X-100), fixed in 4% paraformaldehyde (Electron Microscopy Sciences), and then stained overnight with primary antibody (ID4) diluted in PTN. Following several washes, brains were incubated with the appropriate fluorescently conjugated secondary antibody (1:250) in PTN for 3 hours at room temperature, washed in PTN, and then mounted in Vectashield (Vector Labs). The 1D4 anti-FasII hybridoma (1:20) developed by C. Goodman [50] was obtained from the Developmental Studies Hybridoma Bank (DSHB).

Generation of CRISPR/Cas9 flies

Molecular reagents

pU6-gRNAs: Target-specific sequences were identified sequences using DRSC flyCRISPR optimal target finder (https://www.flyrnai.org/crispr/) for Rrp40 and gRNAs were synthesized as 5’-phosphorylated oligonucleotides, annealed, and ligated into the BbsI sites of pU6-BbsI chiRNA [51].

Homology-directed repair (HDR) templates: HDR donor vectors (Emory Integrated Genomic Core) were constructed by cloning a 3kb fragment of the Rrp40 locus, including a loxP-flanked 3xP3-DsRed cassette inserted downstream of the Rrp40 3’UTR, into KpnI/SmaI sites of the pBlueScript-II vector. Base changes corresponding to G11A and D87A were engineered into this backbone. The 3xP3-DsRed cassette allows positive selection based on red-fluorescence in the adult eye [52].

CRISPR-transformants: Injection of DNA mixtures (500 ng/μl HDR and 250 ng/μl U6-gRNA plasmid) into nos-Cas9 embryos and subsequent screening for dsRed+ transformants was performed by Bestgene, Inc. CRISPR. Edits were confirmed by direct sequencing (S3 Fig).

Lifespan analysis

Lifespan was assessed at 25°C as described previously [53]. In brief, newly eclosed animals were collected, separated by sex, placed in vials (up to 20 per vial), and transferred to fresh vials weekly. Survivorship was scored daily. At least 8 vials of each genotype were tested and averaged to calculate mean and standard deviation. Log-rank tests of survivorship curves were performed using PRISM (GraphPad, San Diego).

Behavioral assays

Negative-geotaxis assay was performed as previously described [54] with some modification. Newly eclosed flies (Rrp40wt, Rrp40G11A, Rrp40D87A) (day 0) were collected, divided into groups of 10, and kept in separate vials. Cohorts of age-matched flies were then transferred to a 25-ml graduated for analysis of climbing response. At least 10 groups (i.e. ~100 flies) were analyzed per genotype.

Immunoblotting

Protein lysates of whole flies or heads were resolved on 4–20% Criterion TGX polyacrylamide gels (Bio Rad), transferred to nitrocellulose membranes, incubated for ≥1hr in blocking buffer (5% non-fat dry milk in 0.1% TBS-Tween), followed by an overnight incubation at 4°C in primary antibody diluted in blocking buffer. Primary antibodies were detected using species-specific horse radish peroxidase (HRP) conjugated secondary antibodies (Jackson ImmunoResearch) and enhanced chemiluminescence (ECL, Sigma). Primary antibodies include: guinea pig anti-Rrp4 (1:1000), rabbit anti-Rrp40 (1:1000), guinea pig anti-Csl4 (1:000), and rat anti-Mtr3 (1:1000) gift of the Lis lab [36, 55].

RNA sequencing analysis

RNA-seq was performed on three replicates of 60 newly-eclosed adult heads per genotype (Rrp40G11A, Rrp40D87A and Rrp40wt). Heads were collected and lysed in TRIzol (ThermoFisher). rRNA was depleted and cDNA libraries were prepared using Truseq RNA sample prep kit (Illumina). The cDNA paired-end reads were sequenced at the Georgia Genomics and Bioinformatics Core at UGA using a NextSeq (150 cycles) PE75 High Output Flowcell. The reads were mapped to the BDGP D. melanogaster (r6.25) genome. Several sequence datasets were downloaded from GenBank and FlyBase for initial assessment of the data including: 1) All Drosophila ribosomal sequences found in Genbank: Drosophila_rRNA.fa; 2) All FlyBase D. melanogaster transcripts from assembly r6.25: dmel_transcripts_r6.25.fa. Adapters were trimmed from raw reads using Trimmomatic (ver. 0.36) [56], and trimmed reads were aligned to the ribosomal sequences using Bowtie2 [57], and only reads which did not map to the ribosome were kept for downstream analysis.

Non-ribosomal reads were then mapped to D. melanogaster r6.25 using Tophat2 [58]. The resulting aligned reads were compared using DESeq2 [59] to identify genes that change significantly (p-value<0.05, >1.5-fold change) in expression. Only genes that were significantly changed compared to the control CRISPR line, Rrp40WT, were used for further analysis.

RNA isolation and qPCR

Total RNA was isolated from heads with TRIzol (Invitrogen) and treated with Turbo DNase (Invitrogen) to degrade contaminating DNA. For qRT-PCR analyses, cDNA was generated using MMLV Reverse transcriptase (Invitrogen) from 1 μg of total RNA, and then used as template for quantitative real-time PCR (qPCR) from duplicate samples of 10 ng cDNA with QuantiTect SYBR Green Master Mix using an Applied Biosystems StepOne Plus real time machine (ABI). Results were analyzed using the ΔΔCT method and normalized to Act5c as fold change relative to control. Oligonucleotide sequences are provided in (S1 Table).

Statistical analysis

All statistical analyses were performed in GraphPad (San Diego, CA). Comparisons between experimental groups were made using one-way analysis of variance (ANOVA), unless noted otherwise. All data are presented as means and standard error of the mean (SEM) (error bars) for at least three independent experiments. Asterisks (*) indicate statistical significance at p-value < 0.05.

Supporting information

S1 Fig [tiff]
Validation of Rrp40 RNAi.

S2 Fig [a]
CRISPR/Cas9-induced Homology-directed recombination (HDR) with a double-stranded DNA donor vector.

S3 Fig [a]
-PCH1b mutations modeled in .

S4 Fig [mrna]
Venn diagrams to illustrate the overlap in transcripts that increase by 5-fold or more in and mutant flies compared to wildtype.

S5 Fig [igv]
Integrative Genomic View (IGV) screenshots of functionally important neuronal transcripts to illustrate the RNA-Seq data obtained.

S1 Table [tif]
Oligonucleotide primer sequences employed for RT-qPCR.

S2 Table [xlsx]
RNA-Seq data analysis of alleles.

S3 Table [xlsx]
RNA-Seq data analysis of alleles.

S1 Video [mov]
Negative geotaxis assay for at Day 4.

S2 Video [mov]
Negative geotaxis assay for at Day 4.

S3 Video [mov]
Negative geotaxis assay for at Day 4.


Zdroje

1. Mitchell P, Petfalski E, Shevchenko A, Mann M, Tollervey D. The exosome: a conserved eukaryotic RNA processing complex containing multiple 3'—>5' exoribonucleases. Cell. 1997;91(4):457–66. doi: 10.1016/s0092-8674(00)80432-8 9390555.

2. Allmang C, Petfalski E, Podtelejnikov A, Mann M, Tollervey D, Mitchell P. The yeast exosome and human PM-Scl are related complexes of 3' —> 5' exonucleases. Genes Dev. 1999;13(16):2148–58. doi: 10.1101/gad.13.16.2148 10465791.

3. Boczonadi V, Muller JS, Pyle A, Munkley J, Dor T, Quartararo J, et al. EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular atrophy and cerebellar hypoplasia. Nat Commun. 2014;5:4287. Epub 2014/07/06. doi: 10.1038/ncomms5287 24989451; PubMed Central PMCID: PMC4102769.

4. Gerstberger S, Hafner M, Ascano M, Tuschl T. Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease. Adv Exp Med Biol. 2014;825:1–55. Epub 2014/09/10. doi: 10.1007/978-1-4939-1221-6_1 25201102; PubMed Central PMCID: PMC4180674.

5. Di Donato N, Neuhann T, Kahlert AK, Klink B, Hackmann K, Neuhann I, et al. Mutations in EXOSC2 are associated with a novel syndrome characterised by retinitis pigmentosa, progressive hearing loss, premature ageing, short stature, mild intellectual disability and distinctive gestalt. J Med Genet. 2016;53(6):419–25. Epub 2016/02/05. doi: 10.1136/jmedgenet-2015-103511 26843489.

6. Wan J, Yourshaw M, Mamsa H, Rudnik-Schoneborn S, Menezes MP, Hong JE, et al. Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. Nat Genet. 2012;44(6):704–8. Epub 2012/05/01. doi: 10.1038/ng.2254 22544365; PubMed Central PMCID: PMC3366034.

7. Mitchell P, Petfalski E, Tollervey D. The 3' end of yeast 5.8S rRNA is generated by an exonuclease processing mechanism. Genes Dev. 1996;10(4):502–13. Epub 1996/02/15. doi: 10.1101/gad.10.4.502 8600032.

8. Liu Q, Greimann JC, Lima CD. Reconstitution, activities, and structure of the eukaryotic RNA exosome. Cell. 2006;127(6):1223–37. Epub 2006/12/19. doi: 10.1016/j.cell.2006.10.037 17174896.

9. Makino DL, Conti E. Structure determination of an 11-subunit exosome in complex with RNA by molecular replacement. Acta Crystallogr D Biol Crystallogr. 2013;69(Pt 11):2226–35. Epub 2013/11/06. doi: 10.1107/S0907444913011438 24189234; PubMed Central PMCID: PMC3817696.

10. Briggs MW, Burkard KT, Butler JS. Rrp6p, the yeast homologue of the human PM-Scl 100-kDa autoantigen, is essential for efficient 5.8 S rRNA 3' end formation. J Biol Chem. 1998;273(21):13255–63. Epub 1998/05/28. doi: 10.1074/jbc.273.21.13255 9582370.

11. Hou D, Ruiz M, Andrulis ED. The ribonuclease Dis3 is an essential regulator of the developmental transcriptome. BMC Genomics. 2012;13:359. Epub 2012/08/03. doi: 10.1186/1471-2164-13-359 22853036; PubMed Central PMCID: PMC3434026.

12. Lim SJ, Boyle PJ, Chinen M, Dale RK, Lei EP. Genome-wide localization of exosome components to active promoters and chromatin insulators in Drosophila. Nucleic acids research. 2013;41(5):2963–80. doi: 10.1093/nar/gkt037 23358822; PubMed Central PMCID: PMC3597698.

13. Yang X, Bayat V, DiDonato N, Zhao Y, Zarnegar B, Siprashvili Z, et al. Genetic and genomic studies of pathogenic EXOSC2 mutations in the newly described disease SHRF implicate the autophagy pathway in disease pathogenesis. Hum Mol Genet. 2019. Epub 2019/10/20. doi: 10.1093/hmg/ddz251 31628467.

14. Pefanis E, Wang J, Rothschild G, Lim J, Chao J, Rabadan R, et al. Noncoding RNA transcription targets AID to divergently transcribed loci in B cells. Nature. 2014;514(7522):389–93. Epub 2014/08/15. doi: 10.1038/nature13580 25119026; PubMed Central PMCID: PMC4372240.

15. Fasken MB, Morton DJ, Kuiper EG, Jones SK, Leung SW, Corbett AH. The RNA Exosome and Human Disease. Methods Mol Biol. 2020;2062:3–33. Epub 2019/11/27. doi: 10.1007/978-1-4939-9822-7_1 31768969.

16. Morton DJ, Kuiper EG, Jones SK, Leung SW, Corbett AH, Fasken MB. The RNA exosome and RNA exosome-linked disease. RNA. 2018;24(2):127–42. Epub 2017/11/03. doi: 10.1261/rna.064626.117 29093021; PubMed Central PMCID: PMC5769741.

17. Muller JS, Giunta M, Horvath R. Exosomal Protein Deficiencies: How Abnormal RNA Metabolism Results in Childhood-Onset Neurological Diseases. J Neuromuscul Dis. 2015;2(Suppl 2):S31–S7. Epub 2015/01/01. doi: 10.3233/JND-150086 27127732; PubMed Central PMCID: PMC4845884.

18. Wan J, Yourshaw M, Mamsa H, Rudnik-Schoneborn S, Menezes MP, Hong JE, et al. Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. Nat Genet. 2012;44(6):704–8. Epub 2012/05/01. doi: 10.1038/ng.2254 22544365; PubMed Central PMCID: PMC3366034.

19. Eggens VR, Barth PG, Niermeijer JM, Berg JN, Darin N, Dixit A, et al. EXOSC3 mutations in pontocerebellar hypoplasia type 1: novel mutations and genotype-phenotype correlations. Orphanet J Rare Dis. 2014;9(1):23. Epub 2014/02/15. doi: 10.1186/1750-1172-9-23 24524299; PubMed Central PMCID: PMC3928094.

20. Rudnik-Schoneborn S, Senderek J, Jen JC, Houge G, Seeman P, Puchmajerova A, et al. Pontocerebellar hypoplasia type 1: clinical spectrum and relevance of EXOSC3 mutations. Neurology. 2013;80(5):438–46. Epub 2013/01/04. doi: 10.1212/WNL.0b013e31827f0f66 23284067; PubMed Central PMCID: PMC3590055.

21. Halevy A, Lerer I, Cohen R, Kornreich L, Shuper A, Gamliel M, et al. Novel EXOSC3 mutation causes complicated hereditary spastic paraplegia. J Neurol. 2014;261(11):2165–9. Epub 2014/08/26. doi: 10.1007/s00415-014-7457-x 25149867.

22. Zanni G, Scotton C, Passarelli C, Fang M, Barresi S, Dallapiccola B, et al. Exome sequencing in a family with intellectual disability, early onset spasticity, and cerebellar atrophy detects a novel mutation in EXOSC3. Neurogenetics. 2013;14(3–4):247–50. Epub 2013/08/27. doi: 10.1007/s10048-013-0371-z 23975261.

23. van Dijk T, Baas F, Barth PG, Poll-The BT. What's new in pontocerebellar hypoplasia? An update on genes and subtypes. Orphanet J Rare Dis. 2018;13(1):92. Epub 2018/06/16. doi: 10.1186/s13023-018-0826-2 29903031; PubMed Central PMCID: PMC6003036.

24. Fasken MB, Losh JS, Leung SW, Brutus S, Avin B, Vaught JC, et al. Insight into the RNA Exosome Complex Through Modeling Pontocerebellar Hypoplasia Type 1b Disease Mutations in Yeast. Genetics. 2017;205(1):221–37. Epub 2016/10/27. doi: 10.1534/genetics.116.195917 27777260; PubMed Central PMCID: PMC5223504.

25. Gillespie A, Gabunilas J, Jen JC, Chanfreau GF. Mutations of EXOSC3/Rrp40p associated with neurological diseases impact ribosomal RNA processing functions of the exosome in S. cerevisiae. RNA. 2017;23(4):466–72. Epub 2017/01/06. doi: 10.1261/rna.060004.116 28053271; PubMed Central PMCID: PMC5340910.

26. de Belle JS, Heisenberg M. Associative odor learning in Drosophila abolished by chemical ablation of mushroom bodies. Science. 1994;263(5147):692–5. Epub 1994/02/04. doi: 10.1126/science.8303280 8303280.

27. Armstrong JD, de Belle JS, Wang Z, Kaiser K. Metamorphosis of the mushroom bodies; large-scale rearrangements of the neural substrates for associative learning and memory in Drosophila. Learn Mem. 1998;5(1–2):102–14. Epub 1999/08/24. 10454375; PubMed Central PMCID: PMC311269.

28. Lee T, Lee A, Luo L. Development of the Drosophila mushroom bodies: sequential generation of three distinct types of neurons from a neuroblast. Development. 1999;126(18):4065–76. Epub 1999/08/24. 10457015.

29. Crittenden JR, Skoulakis EM, Han KA, Kalderon D, Davis RL. Tripartite mushroom body architecture revealed by antigenic markers. Learn Mem. 1998;5(1–2):38–51. Epub 1999/08/24. 10454371; PubMed Central PMCID: PMC311260.

30. Fushima K, Tsujimura H. Precise control of fasciclin II expression is required for adult mushroom body development in Drosophila. Dev Growth Differ. 2007;49(3):215–27. Epub 2007/03/31. doi: 10.1111/j.1440-169X.2007.00922.x 17394600.

31. Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, et al. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell. 2001;107(5):591–603. Epub 2001/12/06. doi: 10.1016/s0092-8674(01)00589-x 11733059.

32. Zinder JC, Lima CD. Targeting RNA for processing or destruction by the eukaryotic RNA exosome and its cofactors. Genes Dev. 2017;31(2):88–100. Epub 2017/02/17. doi: 10.1101/gad.294769.116 28202538; PubMed Central PMCID: PMC5322736.

33. Belair C, Sim S, Kim KY, Tanaka Y, Park IH, and, et al. The RNA exosome nuclease complex regulates human embryonic stem cell differentiation. J Cell Biol. 2019. Epub 2019/07/17. doi: 10.1083/jcb.201811148 31308215.

34. Mistry DS, Chen Y, Sen GL. Progenitor function in self-renewing human epidermis is maintained by the exosome. Cell Stem Cell. 2012;11(1):127–35. Epub 2012/07/10. doi: 10.1016/j.stem.2012.04.022 22770246; PubMed Central PMCID: PMC3392610.

35. McIver SC, Kang YA, DeVilbiss AW, O'Driscoll CA, Ouellette JN, Pope NJ, et al. The exosome complex establishes a barricade to erythroid maturation. Blood. 2014;124(14):2285–97. Epub 2014/08/15. doi: 10.1182/blood-2014-04-571083 25115889; PubMed Central PMCID: PMC4183988.

36. Kiss DL, Andrulis ED. Genome-wide analysis reveals distinct substrate specificities of Rrp6, Dis3, and core exosome subunits. RNA. 2010;16(4):781–91. Epub 2010/02/27. doi: 10.1261/rna.1906710 20185544; PubMed Central PMCID: PMC2844625.

37. Biancheri R, Cassandrini D, Pinto F, Trovato R, Di Rocco M, Mirabelli-Badenier M, et al. EXOSC3 mutations in isolated cerebellar hypoplasia and spinal anterior horn involvement. J Neurol. 2013;260(7):1866–70. Epub 2013/04/09. doi: 10.1007/s00415-013-6896-0 23564332.

38. Di Giovambattista AP, Jacome Querejeta I, Ventura Faci P, Rodriguez Martinez G, Ramos Fuentes F. [Familial EXOSC3-related pontocerebellar hypoplasia]. An Pediatr (Barc). 2017;86(5):284–6. Epub 2016/11/24. doi: 10.1016/j.anpedi.2016.09.011 27876572.

39. Eggens VR, Barth PG, Niermeijer JM, Berg JN, Darin N, Dixit A, et al. EXOSC3 mutations in pontocerebellar hypoplasia type 1: novel mutations and genotype-phenotype correlations. Orphanet J Rare Dis. 2014;9:23. Epub 2014/02/15. doi: 10.1186/1750-1172-9-23 24524299; PubMed Central PMCID: PMC3928094.

40. Bizzari S, Hamzeh AR, Mohamed M, Al-Ali MT, Bastaki F. Expanded PCH1D phenotype linked to EXOSC9 mutation. Eur J Med Genet. 2019. Epub 2019/01/29. doi: 10.1016/j.ejmg.2019.01.012 30690203.

41. Burns DT, Donkervoort S, Muller JS, Knierim E, Bharucha-Goebel D, Faqeih EA, et al. Variants in EXOSC9 Disrupt the RNA Exosome and Result in Cerebellar Atrophy with Spinal Motor Neuronopathy. Am J Hum Genet. 2018;102(5):858–73. Epub 2018/05/05. doi: 10.1016/j.ajhg.2018.03.011 29727687; PubMed Central PMCID: PMC5986733.

42. Howse PE. Brain structure and behavior in insects. Annu Rev Entomol. 1975;20:359–79. Epub 1975/01/01. doi: 10.1146/annurev.en.20.010175.002043 1090240.

43. Wasmuth EV, Zinder JC, Zattas D, Das M, Lima CD. Structure and reconstitution of yeast Mpp6-nuclear exosome complexes reveals that Mpp6 stimulates RNA decay and recruits the Mtr4 helicase. Elife. 2017;6. Epub 2017/07/26. doi: 10.7554/eLife.29062 28742025; PubMed Central PMCID: PMC5553935.

44. Falk S, Bonneau F, Ebert J, Kogel A, Conti E. Mpp6 Incorporation in the Nuclear Exosome Contributes to RNA Channeling through the Mtr4 Helicase. Cell Rep. 2017;20(10):2279–86. Epub 2017/09/07. doi: 10.1016/j.celrep.2017.08.033 28877463; PubMed Central PMCID: PMC5603729.

45. Lorentzen E, Dziembowski A, Lindner D, Seraphin B, Conti E. RNA channelling by the archaeal exosome. EMBO Rep. 2007;8(5):470–6. Epub 2007/03/24. doi: 10.1038/sj.embor.7400945 17380186; PubMed Central PMCID: PMC1866195.

46. Zinder JC, Wasmuth EV, Lima CD. Nuclear RNA Exosome at 3.1 A Reveals Substrate Specificities, RNA Paths, and Allosteric Inhibition of Rrp44/Dis3. Mol Cell. 2016;64(4):734–45. Epub 2016/11/08. doi: 10.1016/j.molcel.2016.09.038 27818140; PubMed Central PMCID: PMC5115963.

47. Ivanov I, Atkinson D, Litvinenko I, Angelova L, Andonova S, Mumdjiev H, et al. Pontocerebellar hypoplasia type 1 for the neuropediatrician: Genotype-phenotype correlations and diagnostic guidelines based on new cases and overview of the literature. Eur J Paediatr Neurol. 2018;22(4):674–81. Epub 2018/04/17. doi: 10.1016/j.ejpn.2018.03.011 29656927.

48. Schwabova J, Brozkova DS, Petrak B, Mojzisova M, Pavlickova K, Haberlova J, et al. Homozygous EXOSC3 mutation c.92G—>C, p.G31A is a founder mutation causing severe pontocerebellar hypoplasia type 1 among the Czech Roma. J Neurogenet. 2013;27(4):163–9. Epub 2013/07/26. doi: 10.3109/01677063.2013.814651 23883322.

49. Wu JS, Luo L. A protocol for dissecting Drosophila melanogaster brains for live imaging or immunostaining. Nat Protoc. 2006;1(4):2110–5. Epub 2007/05/10. doi: 10.1038/nprot.2006.336 17487202.

50. Grenningloh G, Rehm EJ, Goodman CS. Genetic analysis of growth cone guidance in Drosophila: fasciclin II functions as a neuronal recognition molecule. Cell. 1991;67(1):45–57. Epub 1991/10/04. doi: 10.1016/0092-8674(91)90571-f 1913818.

51. Gratz SJ, Wildonger J, Harrison MM, O'Connor-Giles KM. CRISPR/Cas9-mediated genome engineering and the promise of designer flies on demand. Fly (Austin). 2013;7(4):249–55. Epub 2013/10/04. doi: 10.4161/fly.26566 24088745; PubMed Central PMCID: PMC3896497.

52. Gratz SJ, Ukken FP, Rubinstein CD, Thiede G, Donohue LK, Cummings AM, et al. Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila. Genetics. 2014;196(4):961–71. Epub 2014/01/31. doi: 10.1534/genetics.113.160713 24478335; PubMed Central PMCID: PMC3982687.

53. Bauer JH, Goupil S, Garber GB, Helfand SL. An accelerated assay for the identification of lifespan-extending interventions in Drosophila melanogaster. Proc Natl Acad Sci U S A. 2004;101(35):12980–5. Epub 2004/08/26. doi: 10.1073/pnas.0403493101 15328413; PubMed Central PMCID: PMC516504.

54. Pak C, Garshasbi M, Kahrizi K, Gross C, Apponi LH, Noto JJ, et al. Mutation of the conserved polyadenosine RNA binding protein, ZC3H14/dNab2, impairs neural function in Drosophila and humans. Proc Natl Acad Sci U S A. 2011;108(30):12390–5. Epub 2011/07/08. doi: 10.1073/pnas.1107103108 21734151; PubMed Central PMCID: PMC3145741.

55. Andrulis ED, Werner J, Nazarian A, Erdjument-Bromage H, Tempst P, Lis JT. The RNA processing exosome is linked to elongating RNA polymerase II in Drosophila. Nature. 2002;420(6917):837–41. Epub 2002/12/20. doi: 10.1038/nature01181 12490954.

56. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–20. Epub 2014/04/04. doi: 10.1093/bioinformatics/btu170 24695404; PubMed Central PMCID: PMC4103590.

57. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–9. Epub 2012/03/06. doi: 10.1038/nmeth.1923 22388286; PubMed Central PMCID: PMC3322381.

58. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36. Epub 2013/04/27. doi: 10.1186/gb-2013-14-4-r36 23618408; PubMed Central PMCID: PMC4053844.

59. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. Epub 2014/12/18. doi: 10.1186/s13059-014-0550-8 25516281; PubMed Central PMCID: PMC4302049.


Článek vyšel v časopise

PLOS Genetics


2020 Číslo 7
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Důležitost adherence při depresivním onemocnění
nový kurz
Autoři: MUDr. Eliška Bartečková, Ph.D.

Koncepce osteologické péče pro gynekology a praktické lékaře
Autoři: MUDr. František Šenk

Sekvenční léčba schizofrenie
Autoři: MUDr. Jana Hořínková, Ph.D.

Hypertenze a hypercholesterolémie – synergický efekt léčby
Autoři: prof. MUDr. Hana Rosolová, DrSc.

Multidisciplinární zkušenosti u pacientů s diabetem
Autoři: Prof. MUDr. Martin Haluzík, DrSc., prof. MUDr. Vojtěch Melenovský, CSc., prof. MUDr. Vladimír Tesař, DrSc.

Všechny kurzy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#